{"filing":{"accession_number":"0001213900-26-096778","cik":"0001845459","ticker":null,"company_name":"NKGen Biotech, Inc.","form":"8-K","filing_date":"2026-09-02","report_date":"2026-08-05","primary_document":"ea0304079-8k_nkgen.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1845459/000121390026096778/ea0304079-8k_nkgen.htm"},"events":[{"id":31378,"run_id":28785,"accession_number":"0001213900-26-096778","anchor_item_number":"1.01","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.9,"summary":"NKGen Biotech entered into a Fourth Amendment to its Secured Convertible Loan Agreement on August 5, 2026, creating Additional Loan #4 of $1,050,500 principal ($955,000 net proceeds), documented by a new Secured Convertible Promissory Note bearing interest and convertible into common stock at $0.08/share.","company_name":"NKGen Biotech, Inc.","ticker":null,"filing_date":"2026-09-02","form":"8-K","submitted_at":null,"items":[{"id":34233,"accession_number":"0001213900-26-096778","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"NKGen Biotech entered into a Fourth Amendment to its Secured Convertible Loan Agreement on August 5, 2026, creating a new direct financial obligation: an Additional Loan #4 of $1,050,500 principal ($955,000 net proceeds) documented by a new Secured Convertible Promissory Note bearing interest and convertible into common stock. This is a classic debt issuance event. While the instrument includes conversion features and warrant issuance, the core disclosed action is the creation of a new debt obligation, making debt_issuance the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T21:03:19.731272+00:00","company_name":"","ticker":null,"filing_date":""},{"id":34234,"accession_number":"0001213900-26-096778","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Item 2.03 is the dedicated 8-K item for creation of direct financial obligations, typically debt issuances, credit facilities, or term loans. The filing incorporates Item 1.01 by reference, which commonly covers material agreements and transactions. This structure signals a debt or financing event material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T21:03:19.731272+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":31379,"run_id":28785,"accession_number":"0001213900-26-096778","anchor_item_number":"3.02","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"NKGen Biotech issued unregistered equity securities including Consideration Shares in installments, a convertible note (Additional Note #4) convertible at $0.08/share, and a warrant (Additional Warrant #4) exercisable at $0.08/share, all issued under Section 4(a)(2), Regulation D, and/or Regulation S.","company_name":"NKGen Biotech, Inc.","ticker":null,"filing_date":"2026-09-02","form":"8-K","submitted_at":null,"items":[{"id":34235,"accession_number":"0001213900-26-096778","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"NKGen Biotech disclosed an unregistered sale of equity securities under Item 3.02, including: (1) Consideration Shares issued in installments, (2) a convertible note (Additional Note #4) convertible at $0.08/share, and (3) a warrant (Additional Warrant #4) exercisable at $0.08/share. These securities were issued without registration under Section 4(a)(2), Regulation D, and/or Regulation S, which is the hallmark of a dilutive private placement. The conversion and exercise prices suggest potential dilution to existing shareholders, making this material to investors assessing capital structure and ownership.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T21:03:19.731272+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34233,"accession_number":"0001213900-26-096778","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"NKGen Biotech entered into a Fourth Amendment to its Secured Convertible Loan Agreement on August 5, 2026, creating a new direct financial obligation: an Additional Loan #4 of $1,050,500 principal ($955,000 net proceeds) documented by a new Secured Convertible Promissory Note bearing interest and convertible into common stock. This is a classic debt issuance event. While the instrument includes conversion features and warrant issuance, the core disclosed action is the creation of a new debt obligation, making debt_issuance the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T21:03:19.731272+00:00","company_name":"NKGen Biotech, Inc.","ticker":null,"filing_date":"2026-09-02"},{"id":34234,"accession_number":"0001213900-26-096778","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Item 2.03 is the dedicated 8-K item for creation of direct financial obligations, typically debt issuances, credit facilities, or term loans. The filing incorporates Item 1.01 by reference, which commonly covers material agreements and transactions. This structure signals a debt or financing event material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T21:03:19.731272+00:00","company_name":"NKGen Biotech, Inc.","ticker":null,"filing_date":"2026-09-02"},{"id":34235,"accession_number":"0001213900-26-096778","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"NKGen Biotech disclosed an unregistered sale of equity securities under Item 3.02, including: (1) Consideration Shares issued in installments, (2) a convertible note (Additional Note #4) convertible at $0.08/share, and (3) a warrant (Additional Warrant #4) exercisable at $0.08/share. These securities were issued without registration under Section 4(a)(2), Regulation D, and/or Regulation S, which is the hallmark of a dilutive private placement. The conversion and exercise prices suggest potential dilution to existing shareholders, making this material to investors assessing capital structure and ownership.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T21:03:19.731272+00:00","company_name":"NKGen Biotech, Inc.","ticker":null,"filing_date":"2026-09-02"}]}